The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Steroids may make immunotherapy less effective for lung cancer patients, retrospective study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to research led by researchers at Keck Medicine of USC.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

USC study shows how pieces of DNA that regulate gene expression drive prostate cancer

A study, which focused on the DNA switches of prostate cancer cells, reveals insights into enhancers that become active during cancer development and turn on genes linked to the disease. The study found that enhancers work cooperatively in 3D networks, rather than as isolated switches. Some enhancers function as “central hubs” that control many genes, while others play a supporting role. These findings could help with the development of targeted cancer therapies.
Clinical Roundup

Hormone produced by the thymus may reduce age-related inflammation and improve cancer outcomes, USC preclinical study finds

Chronic, low-grade inflammation in the body—a phenomenon known as “inflammaging” because it increases with age—has been linked to many leading causes of illness and death, including cancer, heart disease, metabolic conditions, and neurodegenerative diseases. But scientists have struggled to understand what causes inflammaging or how to reverse its effects.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account